🔗 Share this article

Given that the US proceeds with unprecedented adjustments to its vaccine schedules, a particular individual has emerged unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who first made her name by casting doubt on Covid vaccines throughout the pandemic and has zeroed in on alleged fatalities following COVID-19 immunization in her short position at the FDA.

Scheduled Overhauls to Pediatric Vaccine Schedule

Public health authorities planned to unveil sweeping changes to the childhood immunization program in December, aligning the US with the Danish immunization schedule, according to reports – a substantial departure that would put the US at odds with many the global community with little proof for benefit. The announcement has been delayed until the coming year.

Instead of Vinay Prasad, Tracy Beth Høeg is scheduled to present at the meeting. She was recently named acting director of the FDA’s drug evaluation center, the fifth person to head the division this calendar year.

A New Direction at the Regulatory Body

This interim role could signify a strengthened alliance between the drug and vaccine divisions as Høeg and Prasad consolidate power at the FDA – and it points to a increased emphasis upon rolling back previously authorized immunizations at the FDA.

Dr. Høeg has repeatedly called for ending specific childhood vaccine recommendations in the US in order to be more similar to Denmark, a country with nationalized medicine and a citizenry about the size of Wisconsin’s.

So far public appearances, she has kept her attention on vaccines – usually the purview of Dr. Prasad, director of the FDA’s vaccine center – rather than pharmaceutical oversight.

Doubts Over Qualifications

The appointee has no obvious track record in pharmaceutical research, approval processes or management, which has been standard for past heads of the biologics center. She has been employed at the FDA as a key advisor to the FDA chief and the vaccine center since March.

“She appears not to have the requisite experience” for overseeing the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She has not conducted a clinical trial. She is not versed in managing a sizeable institution. She has no expertise in pharmaceutical oversight.”

Past directors of the center would “grasp legal statutes and the underlying principles of drug development”, commented Janet Woodcock. “Clearly, she doesn’t have the kind of background that prior appointees who ran the center have had.”

This division has an immense portfolio at the FDA, she pointed out.

“Many people just zeroes in on the novel medication approvals, but the generic drug division clears thousands of off-brand pharmaceuticals. There’s a biosimilars division, over-the-counter program and more, and each of these have to be managed,” she noted. “The responsibility you overlook, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a substantial management aspect to the position, which manages more than 5,000 employees. “It’s a huge leadership role, if you execute it properly,” Woodcock said.

Agency Reaction and Disputed Programs

Regarding questions about Høeg’s fitness for the role and whether this assignment signifies greater collaboration among agency officials on immunizations, a spokesperson stated that the “inquiries are based on flawed assumptions”.

“This background matches the functions of her position,” the spokesperson stated, pointing to the months Høeg spent advising the agency head on “drug safety and regulatory science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's new priority voucher program, a disputed expedited drug-approval program that apparently concerned her preceding directors. “How are these medications being picked for this voucher program? Who makes the calls?” Dr. Howard asked. “There’s a lot of lack of transparency occurring at the FDA right now.”

Overall, he said, “the agency appears to be shifting towards less stringent rules of pharmaceuticals, except for shots.”

Established Past Work on Immunizations

Regarding immunizations, Dr. Høeg has a more established, if concerning, history, some experts said. She released a study using unverified crowd-sourced reports to assess the incidence of myocarditis after Covid immunization. She counseled the Florida chief medical officer Joseph Ladapo, who allegedly have changed statistics to indicate COVID-19 vaccinations are more dangerous than they are.

Part of her “desired changes” for the new administration encompassed revising rules for novel immunizations and halting “optional” vaccines, she remarked post-election on a audio program. At the FDA, Dr. Høeg has reportedly floated the idea of excluding young men from receiving COVID-19 vaccinations.

“She is an all-around dogmatist who begins with her preconceived notions and tailors the evidence to retrofit the science in a very deceptive, untruthful way,” Howard stated.

Taking Control and a “Campaign of Retribution”

Høeg joined other dissenters, {like|